Car Deal of the Day: BMW i5 gives luxury electric motoring for £394 a month Car Deal of the Day: BMW i5 gives luxury electric motoring for £394 a month The BMW i5 is a high-tech electric saloon ...

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report ... that have issued a report on the stock in the last year is $192.07. ASND has been the topic of several recent analyst reports.

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. filed to list its shares in Hong Kong, adding to the growing number of publicly traded mainland Chinese firms looking to have their stock ...

Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...

SINGAPORE - Media OutReach Newswire - 7 January 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of Propan, a market leading ...

In the new one, the Sacklers agreed to pay up to $6.5 billion and give up ownership of the company, which would pay nearly $900 million. The maximum contribution from family members is $500 ...

Bothell-based biopharmaceutical company Athira Pharma Inc. (Nasdaq: ATHA) is paying a $4.1 million fine due to allegations it used doctored research to land a National Institutes of Health grant.

Is it the next COVID-19 scare or just market speculation? Should you consider investing in Pharma, Diagnostics, and Hospitals? Dharmesh Kant, Head of Equity Research at Chola Securities ...

The Nifty Pharma index was 0.07 per cent at 21895.35 at the time of writing this report. Benchmark NSE Nifty50 index was down 179.15 points at 23132.65, while the BSE Sensex was 673.34 points at ...

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each ...